AGIO Agios Pharmaceuticals Inc

NASDAQ
$29.68

Agios Pharmaceuticals Inc (AGIO) is expected to report earnings on February 4, 2027, before the market open. The consensus earnings estimate is a loss of $1.19 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -4.8% since its last earnings release on November 5, 2026.

Agios Pharmaceuticals Beat Consensus Estimates
Thursday, November 5, 2026 · 6:30 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 4
Thursday · 6:30 AM ET
Earnings Whisper
-
vs ($1.19)
Rev est $49.12M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $30.22

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Agios Pharmaceuticals Inc

Agios Pharmaceuticals Inc is engaged in the development of medicines to treat cancer metabolism and inborn errors of metabolism, which are a subset of orphan genetic metabolic diseases.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.